Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies brentuximab vedotin in treating patients with advanced
systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab
vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to
grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them